IPH4502 Phase 1 Clinical Trial for Solid Tumors Expressing Nectin-4
/in Clinical Trial, Metastatic, Phase 1/by MaxModified Virus Shows Promise in Shrinking Tumors and Halting Cancer Growth
/in Not PCa related/by MaxWe can’t always win: LAVA-1207 Development Discontinued, Not Related to Safety Issues
/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 3/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi, fellow fighters! Ok, this week I had to take some time off for my PET scan and checkup, so I haven’t gathered as much information as usual to share with you. Nonetheless, what I found is still very interesting and promising! […]
Update on CLS-1025: Precision T Cell Engager Phase 1 Study Expected in Early 2025
/in Clinical Trial, Metastatic, Phase 1/by MaxUMass Scientists Develop Novel Bacteria-Based Cancer Therapy
/in Oncolytic, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 1 Trial: JANX007 Plus JANX013 Combo in mCRPC / mAPMR September 14, 2026
- CRISPR Takes Another Step Forward September 14, 2026
- A STEAP1 ADC That May Turn Tumour Killing Into an Immune Response September 14, 2026
- Soon to be Phase 1 for ICP-B381, a New Bispecific Antibody-Drug Conjugate for mCPRC September 14, 2026